Trial · NCT01536405
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL | Six weeks after vaccination 1 | Sera were tested for VZV Immunoglobulin (IgG) antibody levels by a glycoprotein enzyme-linked immunosorbent assay (gpELISA) |
| Primary | Percentage of Participants With Measles Virus Antibody Levels >=255 mIU/mL | Six weeks after vaccination 1 | Sera were tested for measles virus IgG antibody levels by an ELISA |
| Primary | Percentage of Participants With Mumps Virus Antibody Levels >=10 Units/mL | Six weeks after vaccination 1 | Sera were tested for mumps virus IgG antibody levels by an enzyme-linked immunosorbent assay (ELISA) |
| Primary | Percentage of Participants With Rubella Virus Antibody Levels >=10 International Units/mL (IU/mL) | Six weeks after vaccination 1 | Sera were tested for rubella virus IgG antibody levels by an ELISA |
| Primary | Geometric Mean Titer (GMT) of VZV Antibodies | Six weeks after vaccination 1 | Sera were tested for VZV IgG antibody levels by gpELISA |
| Primary | Geometric Mean Titer (GMT) of Measles Virus Antibodies | Six weeks after vaccination 1 | Sera were tested for measles virus IgG antibody levels by ELISA |
| Primary | Geometric Mean Titer (GMT) of Mumps Virus Antibodies | Six weeks after vaccination 1 | Sera were tested for mumps virus IgG antibody levels by ELISA |
| Primary | Geometric Mean Titer (GMT) of Rubella Virus Antibodies | Six weeks after vaccination 1 | Sera were tested for rubella virus IgG antibody levels by ELISA |
| Primary | Percentage of Participants With Fever (>=102.2°F [39.0°C] or Oral Equivalent) | Up to 5 days after vaccination 1 | |
| Secondary | Percentage of Participants With Fever (>=102.2°F [39.0°C] or Oral Equivalent) | Up to 42 days after each vaccination | |
| Secondary | Percentage of Participants With Zoster-like Rash | Up to 42 days after each vaccination | |
| Secondary | Percentage of Participants With Mumps-like Symptoms | Up to 42 days after each vaccination | |
| Secondary | Percentage of Participants With Measles-like Rash | Up to 42 days after each vaccination | |
| Secondary | Percentage of Participants With Rubella-like Rash | Up to 42 days after each vaccination | |
| Secondary | Percentage of Participants With Varicella-like Rash | Up to 42 days after each vaccination | |
| Secondary | Percentage of Participants With an Injection-site Adverse Event | Up to 5 days after each vaccination | An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs reported were solicited with a Vaccine Report Card. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01536405/registered